Introduction
Surveillance of antimicrobial consumption is important in improving the quality of antimicrobial use. 1 It has a key role in establishing the rationale for the use of antimicrobials. Antimicrobials are among the most costly drug expenditures in Turkey, accounting for 24% of total spending on medicines, and the rate of antimicrobial use has previously been found to be increasing. 2 Turkey has a total population of 71.3 million. Pharmaceuticals accounted for up to 33.5% of the total health expenditure in 2000. 3 An effective social insurance reform (SIR), including substantial changes in drug reimbursement, was implemented by the Turkish Government in 2005. Before the implementation of the SIR, there were various restrictions and limitations for drug reimbursements in the healthcare refund system, which affected almost 70% of the population. Notably, Workers Insurance Organization (SSK), a quasi-governmental insurance organization, did not provide sufficient medicines. Low-income earners, known as green card holders and who make up 14% of the population were not reimbursed for outpatient prescriptions. The more uniform and broader SIR made the prescription and consumption of drugs easier for the governmental and quasigovernmental insurance holders. After the reform, all people insured were provided with full insurance and obtained the right to buy their medicine from any pharmacy, 4 and SSK members began to purchase their prescriptions from private pharmacies.
Limited surveillance data exist on antimicrobial utilization and prescribing patterns in Turkey. The primary aim of this study was to estimate the intensity and pattern of antibiotic consumption in Turkey between 2001 and 2006. Secondly, the study sought to assess the impact of reimbursement policy on antibiotic consumption.
Methods
Annual data on antibiotic sales were provided by the Intercontinental Medical Statistics (IMS) Health Turkey Office. 
Results
Our study showed that nationwide total antibiotic consumption increased systematically and total antibiotic sales increased from 14.62 to 31.36 DDD/1000 inhabitant-days between 2001 and 2006 (Table 1 ). In terms of consumption, penicillins, cephalosporins, macrolides and lincosamides, fluoroquinolones, quinolones and tetracyclines had the highest consumption rates over the 5 year study period. Penicillins were the most prescribed antibiotics in Turkey between 2001 and 2006. Reductions were seen only for amphenicols and these were minimal. When we examined consumption changes in the various classes of antibiotics using ratios, cephalosporin consumption was the greatest, showing a 2.34-fold increase. The cephalosporin group was followed by quinolones and macrolides and lincosamides with 2.01-and 1.93-fold increases, respectively. Table 2) .
Discussion
In Turkey, antibiotics are the most extensively used drugs. Unfortunately, consumption is frequently inappropriate. Enhanced antimicrobial surveillance is a key strategy that can be used to monitor inappropriate antimicrobial use. To the best of our knowledge, this is the first national report of antibiotic consumption in Turkey. This report represents a critical first step in a programme to limit the emergence of antimicrobial resistance through measurement and guidance of antimicrobial prescribing.
After the implementation of the new SIR, almost 70% of the Turkish population was given the opportunity to have a much easier access to prescription drugs including antibiotics. The consumption of antibiotics increased substantially in Turkey after 2005, compared with 2001. The data show that subsidization of antibiotic prescriptions by health insurance systems correlates closely with increased consumption. Restrictions to antibiotic reimbursement as a policy can reduce antibiotic consumption and reverse increasing resistance rates. 7 Therefore, a more restrictive policy and rational antibiotic guides are required.
The antibiotic consumption rate is higher in Turkey than in many European countries (such as Sweden, Denmark, Germany, and Hungary). 8 Penicillin consumption is higher in Turkey, and compared with other European countries, cephalosporin, fluoroquinolone and macrolide consumption rates are also very high in Turkey. The increasing use of fluoroquinolones and cephalosporins is alarming, given that it may increase the risk for emergence of resistant microorganisms. 9 A country's healthcare financing system can directly influence prescribing practice. The Turkish Government's support of prescription drugs greatly influences antibiotic consumption. For example, there are major differences between Turkey and European countries such as Denmark in the use of fluoroquinolones and cephalosporins. Their use was not subsidized by the Danish National Healthcare Service in 1997. 10 Quinolone and cephalosporin consumption in Denmark in the same year was measured to be 0.2 and ,0.05 DDD/1000 inhabitant-days, respectively. However, in our study, consumption of these drugs was estimated to be 3.89 and 6.29 DDD/1000 inhabitant-days, respectively. The reduction in amphenicols we found may be related to decreasing promotion (or lack of promotion) by the pharmaceutical industry of these drugs. In Turkey, no company promoted amphenicols between 2001 and 2006. Given these data, a comprehensive education on the use of antimicrobials should be given to medical students/doctors and strict rules should be enforced to regulate activities of drug companies.
11
This study has several limitations. First, it did not differentiate between consumption in the primary care setting consumption from that in the hospital setting. Our data source did not allow for such differentiation. Countrywide antimicrobial consumption patterns can be affected by many factors. In our study, we tried to show the effects of government policy including a reimbursement system and restrictions in antibiotic prescriptions. However, the implementation of such policies may be uneven such that the impact may be different in the parts of the country. Some hospitals may buy drugs from drug factories and sales are not recorded by the IMS system. As a result, the total antimicrobial utilization in Turkey may be higher than that reported.
In conclusion, antibiotic consumption in Turkey increased substantially in recent years and this was closely related to a new reimbursement policy following the implementation of an SIR.
